Overview

* Scholar Rock ( SRRK ) Q3 net loss widens to $102.2 mln, no revenue recorded

* Operating expenses increased due to apitegromab launch readiness

* Company expects cash reserves to fund operations into 2027

Outlook

* Scholar Rock ( SRRK ) anticipates U.S. launch of apitegromab in 2026

* Company reserves commercial capacity for apitegromab starting Q1 2026

* Scholar Rock expects to start SRK-439 dosing in Q4 2025

Result Drivers

* Research and development expense was $50.5 million, including $5.5 million in stock-based compensation, for the quarter ended September 30, 2025, compared to $48.7 million, including $4.4 million in stock-based compensation, for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.90

Q3 Net -$102.22

Income mln

Q3 -$103.55

Income mln

from

Operatio

ns

Q3 $103.55

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Scholar Rock Holding Corp ( SRRK ) is $45.00, about 33.2% above its November 13 closing price of $30.07

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)